Author: admin

Vernal Keratoconjunctivitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Santen SAS, Novartis, Laboratoires Thea, Allakos Inc., Santen SASl

The Vernal Keratoconjunctivitis Market Forecast report offers an in-depth understanding of the Vernal Keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal Keratoconjunctivitis market trends in the 7MM.

DelveInsight’s “Vernal Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Vernal Keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal Keratoconjunctivitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Vernal Keratoconjunctivitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vernal Keratoconjunctivitis Market Forecast

 

Some of the key facts of the Vernal Keratoconjunctivitis Market Report: 

  • The Vernal Keratoconjunctivitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In the 7MM, there were 620,585 cases of vernal keratoconjunctivitis (VKC) overall in 2021
  • According to estimations, there were 67,389 instances of VKC reported in the United States in 2021
  • Italy has the highest prevalence of VKC among the EU4 and the UK, with 173,432 cases, followed by Germany and France. Spain, on the other hand, had the lowest prevalent population in 2021 with 16,072
  • However, in 2021 in the United States, Mild covers 35.90% of the identified cases, Moderate includes 40.60%, and Severe includes 23.50%.
  • Key Vernal Keratoconjunctivitis Companies: Santen SAS, Novartis, Laboratoires Thea, Allakos Inc., Santen SASl, Astellas Pharma Inc, and others
  • Key Vernal Keratoconjunctivitis Therapies: NOVA22007 ”Ciclosporin”, Cyclosporine A, N-acetyl-aspartyl-glutamate (NAAXIA Sine), AK002, Cyclosporine NOVA22007, FK506, and others
  • The Vernal Keratoconjunctivitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Vernal Keratoconjunctivitis pipeline products will significantly revolutionize the Vernal Keratoconjunctivitis market dynamics.

 

Vernal Keratoconjunctivitis Overview

Young, males are most frequently affected by vernal keratoconjunctivitis (VKC), a persistent allergic conjunctivitis. Even while the majority of allergic conjunctivitis types do not impair vision, VKC is uncommon in that it can cause vision loss if the cornea is damaged.

 

Get a Free sample for the Vernal Keratoconjunctivitis Market Report:

https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market-insight

 

Vernal Keratoconjunctivitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Vernal Keratoconjunctivitis Epidemiology Segmentation:

The Vernal Keratoconjunctivitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Vernal Keratoconjunctivitis
  • Prevalent Cases of Vernal Keratoconjunctivitis by severity
  • Gender-specific Prevalence of Vernal Keratoconjunctivitis
  • Diagnosed Cases of Episodic and Chronic Vernal Keratoconjunctivitis

 

Download the report to understand which factors are driving Vernal Keratoconjunctivitis epidemiology trends @ Vernal Keratoconjunctivitis Epidemiology Forecast

 

Vernal Keratoconjunctivitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vernal Keratoconjunctivitis market or expected to get launched during the study period. The analysis covers Vernal Keratoconjunctivitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Vernal Keratoconjunctivitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Vernal Keratoconjunctivitis Therapies and Key Companies

  • NOVA22007 ”Ciclosporin”: Santen SAS
  • Cyclosporine A: Novartis
  • N-acetyl-aspartyl-glutamate (NAAXIA Sine): Laboratoires Thea
  • AK002: Allakos Inc.
  • Cyclosporine NOVA22007: Santen SAS
  • FK506: Astellas Pharma Inc

 

Discover more about therapies set to grab major Vernal Keratoconjunctivitis market share @ Vernal Keratoconjunctivitis Treatment Market

 

Scope of the Vernal Keratoconjunctivitis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Vernal Keratoconjunctivitis Companies: Santen SAS, Novartis, Laboratoires Thea, Allakos Inc., Santen SASl, Astellas Pharma Inc, and others
  • Key Vernal Keratoconjunctivitis Therapies: NOVA22007 ”Ciclosporin”, Cyclosporine A, N-acetyl-aspartyl-glutamate (NAAXIA Sine), AK002, Cyclosporine NOVA22007, FK506, and others
  • Vernal Keratoconjunctivitis Therapeutic Assessment: Vernal Keratoconjunctivitis current marketed and Vernal Keratoconjunctivitis emerging therapies
  • Vernal Keratoconjunctivitis Market Dynamics: Vernal Keratoconjunctivitis market drivers and Vernal Keratoconjunctivitis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Vernal Keratoconjunctivitis Unmet Needs, KOL’s views, Analyst’s views, Vernal Keratoconjunctivitis Market Access and Reimbursement 

 

To know more about Vernal Keratoconjunctivitis companies working in the treatment market, visit @ Vernal Keratoconjunctivitis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Vernal Keratoconjunctivitis Market Report Introduction

2. Executive Summary for Vernal Keratoconjunctivitis

3. SWOT analysis of Vernal Keratoconjunctivitis

4. Vernal Keratoconjunctivitis Patient Share (%) Overview at a Glance

5. Vernal Keratoconjunctivitis Market Overview at a Glance

6. Vernal Keratoconjunctivitis Disease Background and Overview

7. Vernal Keratoconjunctivitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Vernal Keratoconjunctivitis 

9. Vernal Keratoconjunctivitis Current Treatment and Medical Practices

10. Vernal Keratoconjunctivitis Unmet Needs

11. Vernal Keratoconjunctivitis Emerging Therapies

12. Vernal Keratoconjunctivitis Market Outlook

13. Country-Wise Vernal Keratoconjunctivitis Market Analysis (2019–2032)

14. Vernal Keratoconjunctivitis Market Access and Reimbursement of Therapies

15. Vernal Keratoconjunctivitis Market Drivers

16. Vernal Keratoconjunctivitis Market Barriers

17.  Vernal Keratoconjunctivitis Appendix

18. Vernal Keratoconjunctivitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vernal Keratoconjunctivitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Santen SAS, Novartis, Laboratoires Thea, Allakos Inc., Santen SASl

Schneider Electric to expand, add 455 jobs to Middle Tennessee, bring $85M investment

  • Schneider Electric plans to open new facility in Wilson County and expand an existing facility in Rutherford County.
  • Schneider Electric plans an $85 million investment.

An energy management and automation company plans to expand and add 455 new jobs in Wilson and Rutherford counties, according to the Tennessee Department of Economic and Community Development.

Schneider Electric will create 355 new jobs in Wilson County with the planned opening of a new facility on Maddox Road, according to the state. The company is also planning to expand its Smyrna location and create 100 new jobs there, the state said.

The total investment is estimated at $85 million.

It’s a “big win for our community,” Joint Economic & Community Development Board of Wilson County Executive Director Corey Johns said.

Schneider Electric is a global provider that has seen unprecedented growth in the energy sector, officials said.

The new facility on Maddox will be the company’s first in Wilson County and will be near the Couchville Pike exit and Interstate 840.

The company will be the first tenant in a building that includes about 500,000 square feet of space, Johns said.

The investment in Wilson and Rutherford counties is designed to strengthen production capacity and allow Schneider Electric to better meet customer demand for energy management and automation products.

The company will employ more than 1,900 Tennesseans across facilities in Franklin, Maryville, Memphis, Smyrna and Mt. Juliet once expansion plans are completed, officials noted.

“This project will not only boost the local manufacturing sector and provide job opportunities to more than 355 residents, but it will also strengthen the regional economy and support a more sustainable community for generations to come,” State Sen. Mark Pody said in a statement.

About Schneider Electric

Schneider Electric’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On.

Our mission is to be your digital partner for Sustainability and Efficiency.

We drive digital transformation by integrating world-leading process and energy technologies, endpoint to cloud connecting products, controls, software, and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure, and industries.

We are the most local of global companies. We are advocates of open standards and partnership ecosystems that are passionate about our shared Meaningful Purpose, Inclusive and Empowered values.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric to expand, add 455 jobs to Middle Tennessee, bring $85M investment

Schneider Electric: How AI may be the spark that can lower electricity bills

AI and digitalisation are crucial for the necessary energy transition and to lower CO2 emissions, says the CEO of Schneider Electric, which is launching new solutions at its Innovation Summit in Paris.

The world could save $2 trillion (€1.85 trillion) by 2030 if it implements the necessary technology to decarbonise the energy sector, according to Schneider Electric.

“We have the technology to get rid of 70% of CO2 emissions that are generated by energy,” said CEO Peter Herweck as he called on global leaders from across industries to speed up their efforts.

The CEO of the French multinational company, specialising in digital automation and energy management, was speaking at the company’s flagship Innovation Summit in Paris on Wednesday.

It chose the occasion to announce a number of new solutions, including AI-driven ones, in an effort to accelerate the energy transition.

“We need to use less, but we will be consuming more.”
– Peter Herweck,
CEO of Schneider Electric

Emphasising the need for immediate action, Herweck pointed out that 80% of the CO2 emissions generated today was related to energy. But, he added, only 45% was related to generating energy. That meant 55% was related to the demand side – consumers, in other words – therefore consumers could have a surprisingly strong impact on lowering emissions.

How energy consumption is going to accelerate across the globe

An increasing need for energy will be mainly driven by population growth and also by giving access to people who do not currently have it, Schneider Electric’s CEO said, as he explained that the company anticipates some three billion more people will be in need of energy by 2050.

He expects India, the Middle East and Africa to drive that increase in need and, in those three areas only, sees the necessity for the construction of 100 billion square metres of buildings by 2050. “And it needs to be done in a sustainable way.”

“We need to use less, but we will be consuming more,” he summarised as he spoke about his vision for the future of the energy landscape.

How AI can drive the change

According to Herweck, the solution to lower carbon emissions from the energy sector lies in combining automation, electrification and digitisation. Data centres and artificial intelligence (AI) are in the forefront of their solutions. Investments today are showing a return within 10 years.

Schneider Electric has launched new services, including a new supply chain decarbonisation programme for the minerals and metals industry, a crucial sector for the future of renewable technologies as it provides necessary rare earths and similar materials to produce EV batteries and solar panels, among others. 

The initiative called “Materialize” is a platform where companies dealing with critical resources and materials share their know-how on how to decarbonise their operations. They can also carry out renewable power purchase agreements (PPAs) to reduce carbon emissions across global value chains which typically account for more than 70% of a business’s carbon footprint.

Another trend, the company believes, is that “we all have to manage electricity at home”.  Schneider Electric is tackling that with their platform called Resi9 Energy Center, a home energy management system, that helps homeowners to be a “good shepherd” of their energy resources. 

That is where artificial intelligence comes in and, ideally, does the calculations to lower energy consumption by, for example, providing information on when to charge the car or when to sell the excess energy the solar panels produced on the roof.

The idea is similar when it comes to tackling the need to lower consumption across the various industries.

According to Schneider Electric, sharing data, via, for example, data centre partnerships, is crucial to reach net zero. Generative AI takes part in this process, where sharing data allows companies to analyse good practices, build digital twins, a virtual representation of any operation or problem – all this, to lower unnecessary consumption and tackle energy efficiency which is “half the job,” according to Herweck.

Europe needs to remove some bureaucratic barriers

Europe, as well as many other parts of the world, is behind its targets to reach its net zero goals by 2050. To speed up the adoption of clean energy deployment, the European Commission published its REPowerEU plan in May 2022.

Other initiatives have also been adopted to help the green transition, including the European Green Deal. 

Yet, the development of the energy transition is behind. “We are not at the scale that is necessary to reach the target,” said Gwenaelle Avice Huet Schneider Electric’s Executive Vice President of Europe, adding that it is not investments that are missing, it is the administration, that is very long. 

She urged policymakers to accelerate the necessary procedures. “Now it is all about actions, how to make that happen.” 

The EU still spends €1 billion a day on importing energy, raising questions about the bloc’s competitiveness. The Vice President emphasised that the goal is to build on renewable energy in Europe, and increase competitiveness. “We have to demonstrate that it goes hand in hand with sustainability and it not one or the other”.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric: How AI may be the spark that can lower electricity bills

Sustainability LIVE Dubai: Amr Kandil, Schneider Electric

Amr Kandil, MEA Director of Real Estate segment and New Energy Landscape at Schneider Electric to speak at Sustainability LIVE Dubai – 15 May 2024

Connecting the world’s sustainability leaders, Sustainability LIVE will be returning in 2024 to bring the biggest global businesses together to deliver insightful keynotes, fireside chats, and panel discussions sharing valuable knowledge and real-world experiences. 

The ultimate virtual event for sustainability and ESG leaders in the Middle East and Africa

Serving as the ultimate virtual platform network for the Middle East and Africa, the event connects like-minded peers and companies. 

Join C-suite executives and peers from the sustainability world at Sustainability LIVE Singapore on 15 May. Those attending Sustainability LIVE Dubai will hear from the likes of DP World, Schneider Electric, Coca-Cola Beverages Africa (CCBA), Standard Chartered and many more.

Acclaimed keynote speakers and interactive high-energy panels will be centred around:

• Sustainability Strategy

• ESG

• Net Zero & Planet

• Supply Chain Sustainability

To get your tickets, click here.

Amr Kandil, MEA Director of Real Estate segment and New Energy Landscape at Schneider Electric

About Schneider Electric

Schneider Electric’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On.

Our mission is to be your digital partner for Sustainability and Efficiency.

We drive digital transformation by integrating world-leading process and energy technologies, endpoint to cloud connecting products, controls, software, and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure, and industries.

We are the most local of global companies. We are advocates of open standards and partnership ecosystems that are passionate about our shared Meaningful Purpose, Inclusive and Empowered values.

An experienced energy and sustainable leader, Amr Kandil has been with Schneider Electric for the last decade. At the forefront of the real estate and new energy landscape sectors in the Middle East and Africa, Amr specialises in strategy formulation and execution, with extensive experience in driving energy efficiency and sustainability initiatives.

With a master’s degree in strategic management and a diploma in leadership and strategy, Amr provides organisations with invaluable support to further their energy efficiency and sustainability plans. He particularly focuses on the adoption of sustainable practices and optimising energy consumption.

Amr also collaborates with investors to accelerate the integration of new energy solutions through strategic partnerships and fostering innovation.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sustainability LIVE Dubai: Amr Kandil, Schneider Electric

A Look At The Intrinsic Value Of Schneider Electric S.E. (EPA:SU)

Key Insights

  • The projected fair value for Schneider Electric is €190 based on 2 Stage Free Cash Flow to Equity
  • Current share price of €212 suggests Schneider Electric is potentially trading close to its fair value
  • Analyst price target for SU is €207, which is 9.1% above our fair value estimate

How far off is Schneider Electric S.E. (EPA:SU) from its intrinsic value? Using the most recent financial data, we’ll take a look at whether the stock is fairly priced by projecting its future cash flows and then discounting them to today’s value. Our analysis will employ the Discounted Cash Flow (DCF) model. There’s really not all that much to it, even though it might appear quite complex.

We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.

See our latest analysis for Schneider Electric

Step By Step Through The Calculation

We’re using the 2-stage growth model, which simply means we take in account two stages of company’s growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren’t available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today’s value:

2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Levered FCF (€, Millions) €4.11b €4.81b €5.34b €6.05b €6.56b €6.97b €7.29b €7.55b €7.75b €7.92b
Growth Rate Estimate Source Analyst x9 Analyst x10 Analyst x6 Analyst x1 Est @ 8.41% Est @ 6.17% Est @ 4.61% Est @ 3.51% Est @ 2.75% Est @ 2.21%
Present Value (€, Millions) Discounted @ 7.3% €3.8k €4.2k €4.3k €4.6k €4.6k €4.6k €4.5k €4.3k €4.1k €3.9k

Present Value of 10-year Cash Flow (PVCF) = €43b

We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country’s GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (1.0%) to estimate future growth. In the same way as with the 10-year ‘growth’ period, we discount future cash flows to today’s value, using a cost of equity of 7.3%.

Terminal Value (TV)= FCF2033 × (1 + g) ÷ (r – g) = €7.9b× (1 + 1.0%) ÷ (7.3%– 1.0%) = €127b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= €127b÷ ( 1 + 7.3%)10= €63b

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is €106b. In the final step we divide the equity value by the number of shares outstanding. Compared to the current share price of €212, the company appears around fair value at the time of writing. Valuations are imprecise instruments though, rather like a telescope – move a few degrees and end up in a different galaxy. Do keep this in mind.

Important Assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. If you don’t agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company’s future capital requirements, so it does not give a full picture of a company’s potential performance. Given that we are looking at Schneider Electric as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we’ve used 7.3%, which is based on a levered beta of 1.183. Beta is a measure of a stock’s volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Moving On:

Although the valuation of a company is important, it ideally won’t be the sole piece of analysis you scrutinize for a company. DCF models are not the be-all and end-all of investment valuation. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company’s cost of equity or the risk free rate can significantly impact the valuation. For Schneider Electric, there are three fundamental items you should further examine:

  1. Financial Health: Does SU have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
  2. Future Earnings: How does SU’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: A Look At The Intrinsic Value Of Schneider Electric S.E. (EPA:SU)

AV Access Unveils iDock D23: Top-tier 8K Triple Monitor KVM Switch for Home Office & Gaming on 2 PCs

“AV Access has released the iDock D23 8K KVM switch docking station for triple monitor setup. As the demand for multiple PCs and monitors rises, iDock D23 enables users to effortlessly manage two PCs, three 8K monitors, and numerous peripherals simultaneously.”
The AV Access iDock D23 perfectly combines a high-resolution 8K triple monitor DisplayPort KVM switch with a versatile 12-in-1 docking station. This allows users to easily control 3 monitors, 2 PCs, and multiple peripherals, significantly enhancing efficiency in office, educational, and gaming environments.

AV Access, a leading provider of Pro AV and AV over IP solutions, is excited to introduce the iDock D23 KVM switch docking station, the latest addition to its impressive lineup of KVM switches. With triple monitor capabilities, extensive peripheral connectivity, maximum 8K UHD resolution, ultra-high refresh rates, and other exceptional features, iDock D23 is the ultimate solution for office work, gaming, and learning.

8K Triple Monitor KVM Switch with a 12-in-1 Docking Station

“As the demand for multitasking and multi-monitor setup increases, the adoption of triple monitor KVM switches continue to grow. With AV Access iDock D23, you can switch between two computers while maintaining control over your triple monitor configuration, streamlining workflows and enhancing productivity, ” explained Bill Liao, CTO of AV Access.

Built with 6x DP input ports (supports multi stream transport, 3 in 1 group) and 3x DP output ports, iDock D23 provides seamless switching between a workstation and gaming PC, enabling users to view three monitor screens simultaneously. Moreover, it facilitates the sharing of various peripherals between two computers, such as a mouse, keyboard, printer, scanner, SD card, headphone, and more.

High Refresh Rate & Fast Flexible Switching

This new 8K triple monitor KVM switch also supports ultra-high refresh rates, like 4K@165/144Hz, 3440×1440@144/120Hz, 2560×1440@144/120Hz, 1080P@240Hz, etc, perfect for switching between high-speed racing game sources.

In addition, with the automatic PC wake-up function, it only takes users 2-3 seconds to switch between two PC sources. The 8K DP KVM switch supports switching via the panel button and wired remote controller. It also works flawlessly with various kinds of keyboards for hotkey switching.

“The iDock D23 8K DisplayPort KVM Switch is now available for sale at our official website with an exclusive price of $197.99 with a 10% discount. It’s a must-have for gaming PCs and workstations sharing three screens,” added Bill.

About AV Access

AV Access is the world’s professional manufacturer of advanced Pro AV and AV over IP products, which include HDMI/KVM extenders, splitters, switchers, KVM switches, AV over IP solutions, wireless conference room solutions, etc. Since its establishment, it has been dedicated to offering the ultimate audiovisual experience to the masses with quality-assured and well-designed AV products at honest pricing. AV Access will continue to develop more innovative products and solutions in the fields of smart home, corporate, education, retail, entertainment, health care, etc. Strong R&D, powerful supply chain and excellent management team make AV Access qualified as your faithful partner! Learn more by visiting www.avaccess.com.

Media Contact
Company Name: Actions Global (US) Inc
Contact Person: Shane Jiang
Email: Send Email
Phone: +1-866-629-3923
Address:100 N HOWARD ST STE R
City: City of Spokane
State: Washington 99201
Country: United States
Website: https://www.avaccess.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AV Access Unveils iDock D23: Top-tier 8K Triple Monitor KVM Switch for Home Office & Gaming on 2 PCs

AFTER CLAIRE: In Search of a Habitable Life by John R. Wallis Recognized as a Finalist in International Book Awards Contest

AFTER CLAIRE: In Search of a Habitable Life is recognized for its outstanding writing, design and overall market appeal out of thousands of books submitted into the Book Excellence Awards.

Dr. John Wallis is the multiple award-winning author of AFTER CLAIRE: In Search of a Habitable Life, a gripping psychological crime thriller loosely based on his own life. The book received glowing reviews from BookLife and BookTrib and several international literary awards including a Book Excellence Award and B.R.A.G. Medallion Award. His short story, Helen’s Birthday, was published in Volume IV of the Short Story America Anthology and was a finalist in the Short Story America contest.

John has been a pastoral counselor for over forty years. A United Methodist minister, he graduated from Chicago Theological Seminary in 1975, where he began his association with Samaritan Counseling Centers. He has served as Clinical Director, Executive Director, and Director of Operations. His professional writing credits include an article entitled A Theology of Psychotherapy which was published in the Journal of Pastoral Care and being published in the journal, Lectionary Homiletics three times.

John lives in New Smyrna Beach, Florida.

This one-on-one interview shares John’s background and experience writing AFTER CLAIRE: In Search of a Habitable Life.

Tell us about AFTER CLAIRE: In Search of a Habitable Life.

AFTER CLAIRE is an ambitious, suspense-filled novel that adds a psychological twist to the standard crime genre.

The book has four main characters: Paul, a psychotherapist and single father; his daughter Allie; Paul’s psychotherapy patient, Angela; and Angela’s lover Ricardo, who is the head of a Colombian drug cartel.

Beginning with a fatal car accident that happens when Paul’s wife tells him she wants a divorce, continuing through Paul’s fraught relationship with his nine-year-old Allie, who knows her mother’s death was Paul’s fault, and climaxing with Ricardo’s threats to Paul when he learns Angela wants to leave him, AFTER CLAIRE tells the story of Paul’s struggle to overcome events that push his competence and personal safety beyond their limits.

What inspired you to write AFTER CLAIRE: In Search of a Habitable Life?

When I was working as a psychotherapist, one of my patients was a young woman who wanted to break off her relationship with the head of a Colombian drug cartel. One night, he broke into my office, looking for patient records in order to blackmail her into abandoning treatment. He also threatened to harm me and my family if I kept treating her.

As one of the most dramatic and unforgettable moments of my career, I wanted to share this event as part of a larger narrative, to help readers experience what it was like living through this moment—with all of its drama, suspense and the ensuing consequences.

How did you feel when you found out you received a Book Excellence Award?

I have always been passionate about writing and reading suspense novels, so it was an honor to have my own novel, AFTER CLAIRE, recognized as a Book Excellence Award Finalist in the Suspense category.

How did your background and experience influence your writing?

With years of experience as a psychotherapist and couples’ therapist, I wanted to give readers an authentic look at the psychotherapy process through Paul’s journey coping with guilt, grief and dangerous threats.

Through suspenseful twists and turns, the book offers a realistic look at the skills a therapist needs to possess, the conflicts a therapist may encounter, and the intricate nuances of a doctor-client relationship both during and after therapy. In addition, readers will also see Paul seek therapy himself, highlighting the importance of seeking mental health support in processing pain, trauma and relational challenges.

What is one message you would like readers to remember?

I would like readers to walk away with two key lessons:

For one, to feel the importance of holding fast to your principles. In the book, Paul must find ways to separate his personal issues from the issues of his patients. Even in grave danger, he tries to make the best professional decisions that will keep his daughter safe, while meeting the ethical standards of his profession.

Secondly, to see how fractured relationships can be healed. After the death of his wife, Paul struggles to connect with his daughter, watching her transition from child-like innocence to great loss and heartbreak. As the book progresses, Paul maintains a sense of responsibility towards his client Angela, but knows he must put his daughter’s safety above all.

Purchasing the Book

AFTER CLAIRE: In Search of a Habitable Life has received positive reviews from well-known literary organizations, authors, and reviewers around the world. Booklife writes, “Wallis’ ability to grab the reader’s attention from the very first page deftly propels the story forward…a thoughtful literary thriller.” In addition, BookTrib writes, “A tight mystery novel centered around a believable and enthralling depiction of a man overcome with grief…this psychological crime thriller…will captivate readers throughout.”

The book is available for sale on Amazon. Readers are encouraged to purchase their copy today: https://www.amazon.com/dp/B09MDML991

To connect with John and receive updates on new book releases, visit: https://www.johnrwallis.com. You can also find him on social media on Facebook and Twitter.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AFTER CLAIRE: In Search of a Habitable Life by John R. Wallis Recognized as a Finalist in International Book Awards Contest

Group B Streptococcus Market Report 2040: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Pfizer, Minervax ApS

The Group B Streptococcus Market Forecast report offers an in-depth understanding of the Group B Streptococcus, historical and forecasted epidemiology as well as the Group B Streptococcus market trends in the 7MM.

DelveInsight’s “Group B Streptococcus Market Insights, Epidemiology, and Market Forecast-2040″ report offers an in-depth understanding of the Group B Streptococcus, historical and forecasted epidemiology as well as the Group B Streptococcus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Group B Streptococcus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Group B Streptococcus Market Forecast

 

Some of the key facts of the Group B Streptococcus Market Report: 

  • The Group B Streptococcus market size was valued approximately USD 194 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2040)
  • In April 2023, MinervaX commenced a Phase I clinical trial for its novel GBS vaccine, aiming to evaluate its safety and effectiveness in the older adult demographic affected by Group B Streptococcus (GBS). This trial, conducted at the Centre for Vaccinology (CEVAC) in Ghent, Belgium, will focus on assessing the vaccine’s impact through the administration of two doses to individuals aged 55 to 75, both with and without pre-existing medical conditions.
  • In 2022, the United States dominated the market among the seven major markets, with a value of USD 139 million. Meanwhile, the combined market value of the European Union Four (EU4) and the United Kingdom (UK) amounted to USD 43 million during the same period.
  • According to DelveInsight’s projections, there were approximately 226,722 reported cases of GBS across the 7MM (Seven Major Markets), and these numbers are expected to notably increase by the conclusion of 2040.
  • In the Seven Major Markets (7MM), the European Union Four (EU4) and the United Kingdom (UK) together represented 20% of the overall reported cases of GBS.
  • According to DelveInsight’s analysis, there were approximately 151,932 reported cases of GBS infection in the United States in 2022. These numbers are anticipated to increase over the projected period.
  • The analysis indicates that there were approximately 33,633 cases of type-specific incident invasive GBS infections and 118,299 cases of non-invasive GBS infections in the United States.
  • The market is eagerly anticipating the release of two potential products, GBS-NN/NN2 by MinervaX and Multivalent GBS 6 by Pfizer. These entities have the potential to significantly impact the reduction of newborn and maternal mortality rates among the affected population, addressing a crucial global public health concern.
  • Key Group B Streptococcus Companies: Pfizer, Minervax ApS, and others
  • Key Group B Streptococcus Therapies: GBS-NN/NN2, GBS 6, and others
  • The Group B Streptococcus epidemiology based on gender analyzed that non-invasive GBS infection has a higher incidence than invasive Group B Streptococcus
  • The Group B Streptococcus market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Group B Streptococcus pipeline products will significantly revolutionize the Group B Streptococcus market dynamics.

 

Group B Streptococcus Overview

Group B Streptococcus (GBS) is a type of bacteria commonly found in the intestines, rectum, and genital tract of humans. While it typically doesn’t cause harm in healthy adults, it can lead to serious infections in certain populations, particularly newborns, pregnant women, the elderly, and individuals with weakened immune systems.

 

Get a Free sample for the Group B Streptococcus Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/group-b-streptococcus-gbs-market

 

Group B Streptococcus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2040. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Group B Streptococcus Epidemiology Segmentation:

The Group B Streptococcus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Group B Streptococcus
  • Prevalent Cases of Group B Streptococcus by severity
  • Gender-specific Prevalence of Group B Streptococcus
  • Diagnosed Cases of Episodic and Chronic Group B Streptococcus

 

Download the report to understand which factors are driving Group B Streptococcus epidemiology trends @ Group B Streptococcus Epidemiology Forecast

 

Group B Streptococcus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Group B Streptococcus market or expected to get launched during the study period. The analysis covers Group B Streptococcus market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Group B Streptococcus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Group B Streptococcus Therapies and Key Companies

  • GBS-NN/NN2: Minervax ApS
  • GBS 6: Pfizer

 

Discover more about therapies set to grab major Group B Streptococcus market share @ Group B Streptococcus Treatment Landscape

 

Scope of the Group B Streptococcus Market Report

  • Study Period: 2019–2040
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Group B Streptococcus Companies: Pfizer, Minervax ApS, and others
  • Key Group B Streptococcus Therapies: GBS-NN/NN2, GBS 6, and others
  • Group B Streptococcus Therapeutic Assessment: Group B Streptococcus current marketed and Group B Streptococcus emerging therapies
  • Group B Streptococcus Market Dynamics: Group B Streptococcus market drivers and Group B Streptococcus market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Group B Streptococcus Unmet Needs, KOL’s views, Analyst’s views, Group B Streptococcus Market Access and Reimbursement 

 

To know more about Group B Streptococcus companies working in the treatment market, visit @ Group B Streptococcus Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Group B Streptococcus Market Report Introduction

2. Executive Summary for Group B Streptococcus

3. SWOT analysis of Group B Streptococcus

4. Group B Streptococcus Patient Share (%) Overview at a Glance

5. Group B Streptococcus Market Overview at a Glance

6. Group B Streptococcus Disease Background and Overview

7. Group B Streptococcus Epidemiology and Patient Population

8. Country-Specific Patient Population of Group B Streptococcus 

9. Group B Streptococcus Current Treatment and Medical Practices

10. Group B Streptococcus Unmet Needs

11. Group B Streptococcus Emerging Therapies

12. Group B Streptococcus Market Outlook

13. Country-Wise Group B Streptococcus Market Analysis (2019–2032)

14. Group B Streptococcus Market Access and Reimbursement of Therapies

15. Group B Streptococcus Market Drivers

16. Group B Streptococcus Market Barriers

17.  Group B Streptococcus Appendix

18. Group B Streptococcus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Group B Streptococcus Market Report 2040: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Pfizer, Minervax ApS

Kuntai Group Debuts Advanced Technology-Driven Lamination, Die Cutting, and Bronzing Machines, Providing Superior Manufacturing Solutions Globally

Kuntai Group supplies a wide range of lamination machines, die cutting machines, bronzing machines and other machines made with the latest technology and innovative designs to produce efficient and flawless results for different industries.

Kuntai Group is receiving numerous praises for its lamination machines, die cutting machines, bronzing machines and other machines. It has presented innovative ideas and designs along with reliable performance in their machines. This ensures that the machines are efficient and effective in their designated tasks. The technology used in their machines is state-of-the-art, making them stand out from the competitors. The team of engineers and technicians at this firm continuously work on improving the machines to meet the ever-changing demands of the market. Every feature of the machines is carefully thought out to provide maximum convenience and precision. To check out the latest products and designs from Kuntai Group, clients are advised to visit their website or attend industry exhibitions.

They have presented the hot melt glue laminating machine made with advanced technology. The machine is used widely in industries such as packaging, printing, and automotive interior industries. It has improved both the quality of the products and production efficiency for its clients. It has also reduced the production cost for the clients, which has led to increased profitability. The durability and reliability of the machine have been tested and proven by various clients, making it a popular choice in the market.

Kuntai Machinery

The double belt press machine is another popular product from Kuntai Group. It has been widely used in industries such as shoe making, leather processing, and fabric lamination. The double belt press machine is known for its precise temperature control and pressure distribution, ensuring a smooth and flawless production process. Its compact design also saves space in the factory or production site while still providing efficient results. Users of this machine have reported higher productivity and improved product quality, making it a highly recommended choice among industry professionals.

The UHMW-PE UD Aramid Fabrics Machine is a unique offering from this firm. It uses ultrahigh molecular weight polyethylene (UHMW-PE) and unidirectional (UD) aramid fabrics to produce high-quality materials for bulletproof vests, helmets, car armor, and other personal protective equipment. This machine has helped in providing reliable and durable protection for military personnel, law enforcement officers, and other individuals in high-risk professions. These experts take pride in its ability to contribute to the safety of individuals through their innovative designs and cutting-edge technology.

About Kuntai Machinery 

Kuntai Group is not just a supplier of machines, but a leader in the industry. With over 20 years of experience and expertise, they have built a reputation for providing top-notch products and exceptional customer service. Their commitment to quality and innovation has earned them recognition both locally and internationally. They manufacture machines that cater to various industries and are constantly expanding their product range to meet the diverse needs of their clients. Some of the industries that they serve include packaging, printing, automotive, footwear, and personal protective equipment.

Media Contact
Company Name: Kuntai Machinery
Contact Person: Job Lu
Email: Send Email
Phone: +86 18261228899
Country: China
Website: http://www.kuntai-group.com

Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty

“Most Active Biotech Stocks”
Biotech Stocks To Keep on Top of Radar: Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Actinium Pharmaceuticals (NYSE AMERICAN: ATNM)

In a landscape marked by uncertain economic signals and heated debates over monetary policy, the biotech industry stands out as a beacon of innovation and growth potential. Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), with its groundbreaking advancements in targeted radiotherapies, underscores the burgeoning appeal of biotech investments amidst these turbulent times.

Iomab-B’s Clinical Triumph

Actinium’s Phase 3 SIERRA trial results, recently unveiled at the 50th Annual European Bone Marrow Transplant Society Meeting, have positioned its Iomab-B therapy as a significant contender in the fight against acute myeloid leukemia (AML). Targeting patients 55 years and older with active, relapsed, or refractory AML, Iomab-B has shown promising results, particularly in inducing durable Complete Remission (dCR) and improving overall survival rates among those with the challenging TP53 mutation.

Economic Context and Biotech Sector Performance

While the Federal Reserve maintains interest rates, awaiting clearer indicators of inflation control, the biotech sector sees a silver lining. Despite a dampened outlook for interest rate cuts in the near term—with market expectations now leaning towards September—the environment remains ripe for biotech growth. Historical trends noted by Morgan Stanley suggest that biotech stocks, including those like Actinium, tend to outperform in the months leading up to an initial rate cut.

Indeed, the Nasdaq Biotechnology Index has surged approximately 14% from its October low, illustrating the sector’s resilience and potential for growth despite broader market uncertainty.

Investor Insights

For investors and traders, the implications are clear. The biotech industry, buoyed by robust financing and a favorable mergers and acquisitions outlook, presents a compelling case for investment. Morgan Stanley’s analysis highlights that as the sector anticipates upcoming innovations and more supportive economic conditions post-rate cuts, biotech stocks are likely to continue their upward trajectory.

Future Prospects for Actinium and the Biotech Industry

Recently, Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), saw its price target raised by Maxim from $20 to $30. The adjustment follows the company’s strategic move in acquiring another Ac-225 player, Fusion Pharma (FUSN), in collaboration with AstraZeneca (NASDAQ: AZN). This acquisition is part of a broader wave of consolidation in the radiopharmaceutical space, particularly concerning alpha emitters, a niche but rapidly advancing segment of cancer treatment technologies.

Maxim’s endorsement of ATNM hinges on its positioning within a sparse field of alpha-emitting radiopharmaceuticals, a sector that has seen significant M&A activity. For instance, Bristol Meyers (NYSE: BMY) acquired RayzeBio for $4.1 billion to tap into its Ac-225 pipeline in December, while Lilly (NYSE: LLY) took over POINT Biopharma for $1.4 billion, targeting its portfolio of Lu-177 and Ac-225 based therapies in October 2023. These acquisitions underscore the high “scarcity value” of companies like Actinium, making ATNM a compelling investment candidate amidst the current M&A trend.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) stands at the forefront of this optimistic outlook. With Iomab-B’s potential nearing market readiness and the company’s strategic position in the development of Antibody Radiation Conjugates (ARCs), Actinium is well-placed to capitalize on the dynamics of the current biotech market.

The broader biotech sector’s prospects, reinforced by anticipated financial and operational advancements, suggest a robust framework for growth. Investors are advised to watch closely as Actinium navigates regulatory landscapes and approaches commercial launch phases, potentially yielding significant returns. In summary, amid financial uncertainties and a cautious Federal Reserve stance, the biotech sector, led by innovative companies like Actinium Pharmaceuticals, not only offers a potential hedge against broader economic pressures but also a promising avenue for potentially substantial investment gains.

On Thursday, the biotech stock market saw notable activity among its key players. Eli Lilly and Company (NYSE: LLY) experienced a slight decline, closing at $745.95, down 0.64%, with a trading volume of 1.32 million shares compared to its average of 3.07 million. Novo Nordisk A/S (NYSE: NVO) also saw a decrease, falling 1.43% to $122.75 with a substantial trade volume of 2.72 million shares against an average of 5.07 million. In contrast, Johnson & Johnson (NYSE: JNJ) enjoyed a modest gain, ending the day up 0.67% at $145.74 with a volume of 7.10 million shares, slightly below its usual 7.41 million. Merck & Co., Inc. (NYSE: MRK) had a minor drop of 0.13%, closing at $125.21, while trading 4.78 million shares compared to its average of 8.34 million. Lastly, AbbVie Inc. (NYSE: ABBV) closed higher at $164.66, an increase of 0.25%, with 3.65 million shares changing hands, below its average volume of 5.66 million. These movements reflect the dynamic nature of the biotech sector, with companies experiencing varied levels of activity and shifts in their stock prices.

 

Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of ATNM or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://investorbrandmedia.com/disclaimer/. InvestorBrandMedia.com has been compensated one thousand and six hundred dollars by a 3rd party Bullzeyemedia LLC for content distribution services on ATNM from April 17th to 19th, 2024. We own zero shares of ATNM. InvestorBrandMedia.com has been previously compensated three thousand and five hundred dollars by a 3rd party Bullzeyemedia LLC for content distribution services on ATNM for March 20th to March 28th, 2024. We own zero shares of ATNM. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.InvestorBrandMedia.com is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by InvestorBrandMedia.com or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. InvestorBrandMedia.com is not a fiduciary by virtue of any person’s use of or access to this content.

Sources: 

https://www.tipranks.com/news/the-fly/actinium-pharmaceuticals-price-target-raised-to-30-from-20-at-maxim

https://finance.yahoo.com/news/actinium-announces-iomab-b-phase-120000720.html

https://finance.yahoo.com/news/actinium-announces-clinical-trial-study-111800504.html

https://www.cnbc.com/2024/04/10/biotech-stocks-are-ready-to-break-out-they-just-need-one-more-thing.html?&qsearchterm=biotech

https://finance.yahoo.com/news/actinium-highlights-ability-iomab-b-120000915.html

Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Email: investorbrandmedia@gmail.com
Phone: (954) 593-5597
Country: United States
Website: https://investorbrandmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty